IOBT Insider Trading
Insider Ownership Percentage: 2.30%
Insider Buying (Last 12 Months): $18,632.50
Insider Selling (Last 12 Months): $1,860,484.74
IO Biotech Share Price & Price History
Current Price: $0.95
Price Change: ▲ Price Increase of +0.0499 (5.57%)
As of 01/24/2025 05:00 PM ET
IO Biotech Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
12/23/2024 | Amy Sullivan | CFO | Buy | 10,250 | $0.83 | $8,507.50 | 84,632 | |
12/23/2024 | Mai-Britt Zocca | CEO | Buy | 12,500 | $0.81 | $10,125.00 | 49,891 | |
7/25/2024 | Holdings A/S Novo | Major Shareholder | Sell | 51,522 | $1.33 | $68,524.26 | 4,377,927 | |
5/10/2024 | Holdings A/S Novo | Major Shareholder | Sell | 658,809 | $1.22 | $803,746.98 | 4,429,449 | |
2/9/2024 | Holdings A/S Novo | Major Shareholder | Sell | 658,809 | $1.50 | $988,213.50 | 5,088,258 | |
11/21/2023 | Brian Burkavage | CAO | Buy | 5,000 | $0.99 | $4,950.00 | 6,500 | |
8/9/2023 | Vivo Capital Ix, Llc | Major Shareholder | Buy | 3,157,894 | $1.90 | $5,999,998.60 | 3,157,894 | |
3/17/2023 | Amy Sullivan | CFO | Buy | 25,000 | $2.32 | $58,000.00 | 25,000 | |
IO Biotech Institutional Trading History
Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
---|
10/24/2024 | Novo Holdings A S | 3,354,449 | $3.52M | 0.2% | -24.3% | 5.092% | |
8/20/2024 | Novo Holdings A S | 4,429,449 | $5.18M | 0.3% | -12.9% | 6.723% | |
8/15/2024 | Armistice Capital LLC | 1,545,000 | $1.81M | 0.0% | -10.4% | 2.345% | |
8/12/2024 | XTX Topco Ltd | 26,555 | $31K | 0.0% | +67.4% | 0.040% | |
8/9/2024 | Renaissance Technologies LLC | 180,800 | $0.21M | 0.0% | +8.1% | 0.274% | |
2/15/2024 | PFM Health Sciences LP | 2,341,107 | $4.40M | 0.3% | +73.0% | 3.554% | |
2/13/2024 | Stonepine Capital Management LLC | 1,666,037 | $3.13M | 1.4% | -15.7% | 2.529% | |
2/13/2024 | Armistice Capital LLC | 1,924,000 | $3.62M | 0.0% | -10.4% | 2.920% | |
11/15/2023 | Armistice Capital LLC | 2,148,000 | $3.03M | 0.0% | N/A | 3.260% | |
11/14/2023 | Stonepine Capital Management LLC | 1,975,308 | $2.79M | 0.9% | N/A | 2.998% | |
11/14/2023 | Pivotal bioVenture Partners Investment Advisor LLC | 864,197 | $1.22M | 0.5% | N/A | 1.312% | |
11/8/2023 | Vivo Capital LLC | 6,173,439 | $8.71M | 1.1% | +104.7% | 9.371% | |
7/25/2023 | Summit Trail Advisors LLC | 43,744 | $86K | 0.0% | N/A | 0.152% | |
2/14/2023 | RA Capital Management L.P. | 1,127,260 | $2.59M | 0.1% | -39.3% | 3.911% | |
11/14/2022 | Psagot Value Holdings Ltd. Israel | 40,846 | $0.11M | 0.0% | N/A | 0.142% | |
11/2/2022 | Victory Capital Management Inc. | 43,741 | $0.12M | 0.0% | N/A | 0.152% | |
2/15/2022 | Samsara BioCapital LLC | 1,120,437 | $7.17M | 1.4% | N/A | 3.888% | |
2/15/2022 | Capital World Investors | 1,235,000 | $8.11M | 0.0% | N/A | 4.286% | |
2/14/2022 | Soleus Capital Management L.P. | 672,734 | $4.31M | 0.4% | N/A | 2.335% | |
2/14/2022 | Novo Holdings A S | 3,277,932 | $20.98M | 1.0% | N/A | 11.376% | |
Data available starting January 2016
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Read More on IO Biotech
Volume
230,860 shs
Average Volume
147,149 shs
Market Capitalization
$62.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.24
Who are the company insiders with the largest holdings of IO Biotech?